International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 12.23.2021
celebrating 2022
490x245 fda.png
Breaking News: FDA Authorizes Two Oral Antiviral Treatments for COVID-19
The FDA authorized two oral antiviral treatments for COVID-19: Molnupiravir and Paxlovid. Molnupiravir is for adults who are vulnerable to becoming severely ill from COVID and for whom alternative COVID treatment options authorized by the FDA are “not accessible or clinically appropriate,” according to the New York Times. The treatment is expected to be available in a few weeks. The first-of-its-kind treatment, Paxlovid, has been found to be highly protective against severe illness, according to a report in the New York Times, which adds that the treatment for high-risk patients 12 and older could be available within a few days.
year in review blog 2021
A Year in Review: Looking Back at Dr. Durie’s 2021 Blogs
2021 was both a productive and challenging year. Glean new insights from Dr. Brian G.M. Durie’s blogs — from developing a mental survival strategy to build and maintain resilience, to a deeper understanding of the COVID-19 Omicron variant, to breakthroughs made by the iStopMM project in myeloma research and treatment, to new developments in the ASCENT trial — Dr. Durie’s blogs are brimming with a wealth of information throughout 2021.
read the blogs button
Best of ASH 2021 Replay Banner
View the Highlights and Takeaways from the Best of ASH 2021 Webinar
In the Best of ASH 2021 Webinar, Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from this year’s American Society of Hematology (ASH) conference. Get to know the highlights of the top myeloma abstracts that were presented at ASH 2021 in the video and the downloadable slideshow.
support group leaders at ash 2021
Learn New Insights from IMF Support Group Leaders via the ASH 2021 Blogs
With the conclusion of the 63rd American Society of Hematology Annual Meeting, IMF Support Group Leaders have a lot of insights and new knowledge to share via their ASH 2021 blogs. Read through these information-laden accounts of the ASH event from Day 1 to Day 3 as they elaborate on the latest clinical updates in myeloma research, therapies, and practice strategies.
Dr. Mikhael speaking on facebook live banner
IMF Chief Medical Officer Dr. Joseph Mikhael Addresses Disparities in Myeloma Care
On December 15, 2021, IMF Chief Medical Officer Dr. Joseph Mikhael engaged the myeloma community on Facebook to address disparities in myeloma care as they apply to the African American community. Watch the replay of the Facebook livestream on YouTube.
The IMF Office Will Be CLOSED for the Holidays
The IMF office will be closed for the holidays from December 24, 2021 and will resume regular business hours on Tuesday, January 4, 2022. If you have urgent questions about your year-end gift or for Major Gift Planning, please email Lynn Green, Senior Vice President for Philanthropy at
ask doctor durie video image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
Catch up on the IMF’s educational series, “Ask Dr. Durie.”
Watch Now
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Ongoing Replays
Watch the Replay
IMWG Conference Series: ASH 2021

Watch the Replay
Advances in Myeloma Treatments Webinar

Watch the Replay
COVID-19 and Myeloma Webinar

Watch the Replay
Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page